- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic colorectal cancer Epithelial ovarian, fallopian tube, or primary peritoneal cancer, cervical cancer, Stage IV glioma, non-small cell lung cancer (NSCLC)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 933KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 55KB)
Bevacizumab – November 2020
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Mvasi®
Last updated
5 March 2021